Systemic lupus erythematosus (SLE) is the prototype of autoimmune diseases and is characterized by multisystemic affection. Hospitalization is a frequent eventuality in the course of the disease with a rate of 0.50 admissions/person-year estimated; infections and disease activity explain the highest percentage of admissions, risk factors depend on the population studied, among which are cardiopulmonary disease, elevated creatinine, thrombocytopenia, high disease activity and use of immunosuppression, however, the risk factors in the Mexican population are unknown.To identify risk factors for hospitalization in patients with generalized lupus erythematosus, and as a secondary result, identify the main causes of hospitalization in our population.Observational, analytical, case-control and ambilective study of patients with a diagnosis of SLE at the Hospital Central Dr. Ignacio Morones Prieto in San Luis Potosí, Mexico, evaluated from January 2019 to October 2020; for each hospitalized patient with SLE, a non-hospitalized patient with SLE evaluated in the Rheumatology outpatient clinic was taken as a control, to establish a 1: 1 relationship. Continuous variables were expressed as mean or median; and standard deviation or interquartile ranges (IQR) according to the distribution. The categorical variables were expressed in proportion. The comparison of continuous variables was carried out with the unpaired Student’s t test or Mann Whitney’s U according to their distribution, while the categorical variables were compared with Fisher’s exact test or X 2 and logistic regression analysis was performed.A total of 202 patients were collected, 179 were women (88.6%); of all patients, 89 (45.1%) were hospitalized, who were younger at diagnosis and time of evolution of the disease and greater SLEDAI and accumulated damage than non-hospitalized patients. The main causes of hospitalization were disease activity in 60.7% of cases, with kidney disease being the most important, followed by infectious in 22.5% and pharmacological toxicity in 5.6%. In the multivariate analysis, the risk factors associated with hospitalization identified were creatinine (p 0.018), CRP (p 0.046), neutrophils (p 0.013), constitutional condition (p 0.044), hematological (p 0.003) and renal (p. p 0.004), see Table 1. Factors associated with mortality were creatinine (p 0.022), INR (0.019), days of ICU stay (p 0.020) and the use of vasopressors (p 0.003). The use of antimalarials was a protective factor for hospitalization with p 0.0003. Survival analysis was performed where it was observed that patients with infection acquired in the hospital had a lower probability of survival with p 0.012.In our center, disease activity continues to be the most frequent cause of hospitalization and elevated creatinine is a risk factor for hospitalization and mortality in patients with SLE. In-hospital infections were a factor of poor survival.[1]Lee J, Park D, Kang J, Choi S, Yim Y, Kim J, et al. The rate of and risk factors for frequent hospitalization in systemic lupus erythematosus: results from the Korean lupus network registry. Lupus 2016. DOI: 10.1177/0961203316640916.[2]Li D, Madhoun H, Jarjour W. Determining risk factors that increase hospitalizations in patients with systemic lupus erythematosus. Lupus 2018. DOI. 10.1177/0961203318770534.Table 1.Multivariate analysis of factors associated with hospitalization in patients with SLEORCI 95%pAge of diagnosis1.040.993 - 1.110.097Previos prednisone dose1.171.030 – 1.410.069Use of antimalarials0.040.006 - 0.210.003Hemoglobin0.780.57 – 1.010.074Neutrophils1.581.13 – 2.390.013Creatinine2.961.40 – 8.860.018CRP1.160.99 – 1.360.046Constitutional condition9.191.24 – 105.220.044Hematological condition34.53.82 – 517.490.003Renal condition16.052.66 – 133.420.004Cardiopulmonary condition19.790.84 – 843.460.081None declared
[1]
B. Rovin,et al.
Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis.
,
2020,
The New England journal of medicine.
[2]
Andreas Radbruch,et al.
Targeting CD38 with Daratumumab in Refractory Systemic Lupus Erythematosus.
,
2020,
The New England journal of medicine.
[3]
M. Infantino,et al.
European League against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus: the laboratory immunologist’s point of view
,
2019,
Annals of the Rheumatic Diseases.
[4]
D. Gladman,et al.
2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus
,
2019,
Arthritis & rheumatology.
[5]
L. Rönnblom,et al.
Interferon pathway in SLE: one key to unlocking the mystery of the disease
,
2019,
Lupus Science & Medicine.
[6]
T. J. Kim,et al.
The rate of and risk factors for frequent hospitalization in systemic lupus erythematosus: results from the Korean lupus network registry
,
2016,
Lupus.
[7]
R. Fischer-Betz,et al.
Age-specific prevalence of diagnosed systemic lupus erythematosus in Germany 2002 and projection to 2030
,
2014,
Lupus.
[8]
Thomas Häupl,et al.
Sialic acid-binding Ig-like lectin 1 expression in inflammatory and resident monocytes is a potential biomarker for monitoring disease activity and success of therapy in systemic lupus erythematosus.
,
2008,
Arthritis and rheumatism.